[1] |
Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease[J]. Gut, 2022, 71(1): 194-209.
doi: 10.1136/gutjnl-2021-324305
URL
|
[2] |
中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1989-1999.
|
[3] |
Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics[J]. Gut, 2016, 65(11): 1895-1905.
doi: 10.1136/gutjnl-2015-311292
URL
|
[4] |
Kalas MA, Chavez L, Leon M, et al. Abnormal liver enzymes: a review for clinicians[J]. World J Hepatol, 2021, 13(11): 1688-1698.
doi: 10.4254/wjh.v13.i11.1688
URL
|
[5] |
曹旬旬, 高月求, 张文宏, 等. 基于上海市住院慢性肝病患者胆汁淤积患病率的调查研究[J]. 中华肝脏病杂志, 2015, 23(8): 569-573.
|
[6] |
Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis-a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323.
doi: S0168-8278(17)32196-7
pmid: 28802875
|
[7] |
Appanna G, Kallis Y. An update on the management of cholestatic liver diseases[J]. Clin Med (Lond), 2020, 20(5): 513-516.
|
[8] |
Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver[J]. Mol Aspects Med, 2017, 56: 45-53.
doi: 10.1016/j.mam.2017.06.001
URL
|
[9] |
Wu H, Chen C, Ziani S, et al. Fibrotic events in the progression of cholestatic liver disease[J]. Cells, 2021, 10(5): 1107.
doi: 10.3390/cells10051107
URL
|
[10] |
李飞, 陆伦根. 胆汁淤积和黄疸的诊断与鉴别诊断[J]. 内科理论与实践, 2018, 13(6): 385-387.
|
[11] |
Šarenac TM, Mikov M. Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients[J]. Front Pharmacol, 2018, 9: 939.
doi: 10.3389/fphar.2018.00939
pmid: 30319399
|
[12] |
宋丹军, 潘家琪, 李鹏旭, 等. 溶血磷脂酰胆碱在肝脏疾病中的研究进展[J]. 中国药理学通报, 2014, 12: 1642-1646.
|
[13] |
Reichert MC, Hall RA, Krawczyk M, et al. Genetic determinants of cholangiopathies: molecular and systems genetics[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4): 1484-1490.
doi: 10.1016/j.bbadis.2017.07.029
URL
|
[14] |
Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: from pathophysiology to clinical practice[J]. J Hepatol, 2015, 62(1 Suppl): S6-S14.
doi: 10.1016/j.jhep.2015.02.025
URL
|
[15] |
García-Giménez JL, Seco-Cervera M, Tollefsbol TO, et al. Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory[J]. Crit Rev Clin Lab Sci, 2017, 54(7-8): 529-550.
doi: 10.1080/10408363.2017.1410520
URL
|
[16] |
van der Kolk JH, Pacholewska A, Gerber V. The role of microRNAs in equine medicine: a review[J]. Vet Q, 2015, 35(2): 88-96.
doi: 10.1080/01652176.2015.1021186
pmid: 25695624
|
[17] |
Kim YC, Jung H, Seok S, et al. MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice[J]. Hepatology, 2020, 71(6): 2118-2134.
doi: 10.1002/hep.30966
URL
|
[18] |
Navaneethan U, Lourdusamy V, Gk Venkatesh P, et al. Bile proteomics for differentiation of malignant from benign biliary strictures[J]. Gastroenterol Rep (Oxf), 2015, 3(2): 136-143.
|